| Literature DB >> 31137791 |
Gyeong Jin Lee1, Tae-Il Kim2,3.
Abstract
i-motif is cytosine (C)-rich oligonucleotide (ODN) which shows pH-responsive structure change in acidic condition. Therefore, it has been utilized for the trigger of intercalated drug release, responding to environmental pH change. In this study, 2.76 molecules of i-motif binding ODNs (IBOs) were conjugated to each hyaluronic acid (HA) via amide bond linkages. Synthesis of HA-IBO conjugate (HB) was confirmed by FT-IR and agarose gel electrophoresis with Stains-All staining. After hybridization of HB with i-motif ODN (IMO), it was confirmed that doxorubicin (DOX) could be loaded in HB-IMO hybrid structure (HBIM) with 65.6% of drug loading efficiency (DLE) and 25.0% of drug loading content (DLC). At pH 5.5, prompt and significant DOX release from HBIM was observed due to the disruption of HBIM hybrid structure via i-motif formation of IMO, contrary to pH 7.4 condition. Then, HBIM was complexed with low molecular weight polyethylenimine (PEI1.8k), forming positively charged nanostructures (Z-average size: 126.0 ± 0.4 nm, zeta-potential: 16.1 ± 0.3 mV). DOX-loaded HBIM/PEI complexes displayed higher anticancer efficacy than free DOX in A549 cells, showing the potential for pH-responsive anticancer drug delivery systems.Entities:
Keywords: drug delivery systems; hyaluronic acid; i-motif; nanostructure; pH-responsive; polyethylenimine
Year: 2019 PMID: 31137791 PMCID: PMC6572266 DOI: 10.3390/pharmaceutics11050247
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Hybridization behavior of i-motif ODN (IMO) and i-motif binding ODN (IBO). (A) Agarose gel electrophoresis result. (B) EtBr binding assay result. Relative fluorescence intensity (RFI).
Figure 2Fluorescence measurement of doxorubicin (DOX) and IBM/DOX in water and dimethyl sulfoxide (DMSO).
Figure 3FT-IR spectra of HA and HA-IBO conjugate (HB).
Figure 4Stains-All staining result of HB, HBIM, and HA in agarose gel electrophoresis.
Figure 5DOX release behavior of HBIM/DOX at pH 7.4 and pH 5.5.
Figure 6MTT assay result in (A) HeLa cells and (B) A549 cells (Relative cell viability (RCV)).
Figure 7Anticancer activity of HBIM/DOX and HBIM/DOX/PEI in (A) HeLa cells and (B) A549 cells.